General Western Blot Reagents
Abcam Venlafa x ine hydrochloride, Serotonin-norepinephrine reuptake inhibitor, 10MG
MW 313.87 g/mol, Purity >99%. Serotonin-norepinephrine reuptake inhibitor. Ki values are 82 and 2480 nM for SERT and NET, respectively. Displays 30-fold higher affinity for SERT than NET in vitro. Antidepressant.
The product is subject to the following: Abcam Restricted Use Statement
Abcam NBD-Cl, Amine-reactive fluorogenic dye, 1G
MW 199.55 Da, Purity >98%. Amine-reactive, fluorogenic dye. Forms green fluorescent adducts with aliphatic amines and thiols. Labels proteins, peptides, amino acids and other biomolecules.
The product is subject to the following: Abcam Restricted Use Statement
Abcam BHHCT, Fluorescent sensitizer for Eu3+- labelling, 5MG
MW 804.9 Da, Purity >90%. Fluorescent sensitizer for Eu3+- labelling. Increases luminescence intensity 11 fold. Persists as an Eu3+ complex for 500 μs typical of the Eu3+ oxidation state. Measures peroxidase activity and oxidative stress levels.
The product is subject to the following: Abcam Restricted Use Statement
Abcam BML 284, Wnt signaling activator, 25MG
MW 350.4 Da, Purity >98%. Cell-permeable Wnt signaling activator. Induces β-catenin and TCF-dependent transcriptional activity (EC₅₀ = 0.7 μM). Activates Wnt without inhibiting GSK-3β.Shows developmental effects in vivo. .
The product is subject to the following: Abcam Restricted Use Statement
Abcam MMP-2/MMP-9 Inhibitor I, MMP-2/MMP-9 inhibitor, 5MG
MW 381.4 Da, Purity >99%. Matrix metalloproteinase inhibitor of MMP-2/MMP-9. Synergizes with TNF-α to induce apoptosis in cancer cells. Active in vitro.
The product is subject to the following: Abcam Restricted Use Statement
Abcam beta-Elemene, Anticancer agent, 25MG
MW 204.35 Da. Anticancer agent. Induces G₂M cell cycle arrest and apoptosis. Induces caspase-3, -7 and -9 activities. Decreases Bcl-2 expression. Induces mitochondrial release of cytochrome c. Inhibits microtubule polymerization. Downregulates uPA, uPAR, MMP-2, and MMP-9 expression. Shows antiproliferative effects. Shows antitumor effects in vivo. .
The product is subject to the following: Abcam Restricted Use Statement
Abcam NPS 2143 hydrochloride, Ca2+-sensing receptor antagonist, 50MG
MW 445.4 Da, Purity >99%. Potent, selective Ca2+-sensing receptor antagonist (IC50 = 43 nM). Stimulates parathyroid hormone secretion (EC50 = 41 nM). Shows antihypertensive effects *in vivo.* Orally active.
The product is subject to the following: Abcam Restricted Use Statement
Abcam N-Palmitoyl phosphatidylethanolamine, Endogenous lipid anorectic hormone, 5MG
MW 930.4 g/mol, Purity >98%. Endogenous lipid which significantly reduced food intake in a dose-dependent fashion when administered to rats and mice without causing taste aversion. Found to enter the brain (concentrating in the hypothalamus) when administered systemically and also reduced food intake when infused intracerebroventricularly (nanomolar concentrations), suggesting that mediation of effects is via the CNS. Chronic infusion resulted in a reduction of both food intake and body weight, suggesting that NAPE and long-acting NAPE analogs may be novel therapeutic targets for the treatment of obesity.
The product is subject to the following: Abcam Restricted Use Statement
ABBEXA LLC Human Potassium Voltage-Gated Channel Subfamily B Member 1 (KCNB1) ELISA Kit (Size: 96 tests)
Human Potassium Voltage-Gated Channel Subfamily B Member 1 (KCNB1) ELISA Kit is an ELISA Kit for the in vitro quantitative measurement of Human KCNB1 concentrations in tissue homogenates, cell lysates and other biological fluids.
Abcam Resorufin methyl ether (7-Meth)o x yresorufin), Fluorometric cytochrome P450 substrate, 1MG
MW 227.21 Da. Fluorometric competitive cytochrome P450 substrate. Resorufin (ab145435) butyrate analog. Shows selectivity for CYP1A (Ki = 20 μM, dealkylation 0.5 μM substrate).
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ledol, Antifungal agent, 500MG
MW 222.37 Da, Purity >95%. Antifungal agent. Putative anti-inflammatory and antinociceptive agent. May show expectorant, anti-inflammatory, antitussive and antinociceptive effects in vivo. Orally active.
The product is subject to the following: Abcam Restricted Use Statement
Abcam beta-Elemene, Anticancer agent, 500MG
MW 204.35 Da. Anticancer agent. Induces G₂M cell cycle arrest and apoptosis. Induces caspase-3, -7 and -9 activities. Decreases Bcl-2 expression. Induces mitochondrial release of cytochrome c. Inhibits microtubule polymerization. Downregulates uPA, uPAR, MMP-2, and MMP-9 expression. Shows antiproliferative effects. Shows antitumor effects in vivo. .
The product is subject to the following: Abcam Restricted Use Statement
Abcam Rp-8-Br-cGMPS, cGMP blocker, 500UG
MW 462.15 Da, Purity >98%. cGMP blocker. Competitively inhibits relaxation elicited by 8-Br-cGMP in isolated rabbit aorta contracted by phenylephrine at 30 μM.
The product is subject to the following: Abcam Restricted Use Statement
Abcam DCIA, Fluorescent thiol-reactive neutral probe, 10MG
MW 490.33 g/mol, Purity >85%. Fluorescent thiol-reactive neutral probe. Self-quenching until it reacts with thiol groups and regains its strong fluorescence.
The product is subject to the following: Abcam Restricted Use Statement
Abcam DCIA, Fluorescent thiol-reactive neutral probe, 100MG
MW 490.33 g/mol, Purity >85%. Fluorescent thiol-reactive neutral probe. Self-quenching until it reacts with thiol groups and regains its strong fluorescence.
The product is subject to the following: Abcam Restricted Use Statement